Literature DB >> 1676622

Treatment of delirium in the critically ill patient.

D N Fish1.   

Abstract

The clinical use of neuroleptics, benzodiazepines, narcotic analgesics, barbiturates, and neuromuscular blockers to manage delirium and agitation in the intensive-care setting is reviewed. Delirium is the most commonly encountered mental disturbance in critically ill patients and may be precipitated by factors such as physical illness, medications, pain, and emotional stress. If agitation cannot be controlled through nonpharmacologic means, pharmacologic intervention may be necessary. Haloperidol is the neuroleptic of choice for rapid control of delirium and agitation in the critically ill patient. It has few adverse effects in most patients, even at high doses, although it can cause extrapyramidal symptoms. Among the benzodiazepines, lorazepam should be considered a first-line agent. It may be used alone or in combination with haloperidol (or another neuroleptic). Midazolam is suitable for administration by continuous i.v. infusion in the intensive-care setting because of its water solubility, short half-life, and short duration of action. The sedative effects of narcotics may be advantageous in patients with both agitation and pain. Barbiturates are not recommended for routine use in the treatment of delirium and agitation. The use of neuromuscular blocking agents such as pancuronium bromide and metocurine iodide may be necessary when other therapies have failed. Haloperidol and the benzodiazepines, alone or in combination, are the drugs of choice for treatment of acute agitation and delirium in critically ill patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676622

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  9 in total

Review 1.  Delirium: optimising management.

Authors:  D J Meagher
Journal:  BMJ       Date:  2001-01-20

Review 2.  Clinical pharmacology of old age syndromes.

Authors:  C Broadhurst; K C M Wilson; M T Kinirons; A Wagg; J K Dhesi
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 3.  Drug-induced delirium. Incidence, management and prevention.

Authors:  G L Carter; A H Dawson; R Lopert
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 4.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 5.  Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection.

Authors:  Linda L Liu; Michael A Gropper
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Delirium and epilepsy.

Authors:  Peter W Kaplan
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

7.  Use of neuroleptics in a general hospital.

Authors:  Raquel Barba; Javier Garay; Helena Martín-Alvarez; Carlos Herrainz; Virgilio Castellanos; Isabel Gonzalez-Anglada; Angel Puras
Journal:  BMC Geriatr       Date:  2002-05-03       Impact factor: 3.921

Review 8.  Delirium in the elderly. Optimal management.

Authors:  J M Flacker; E R Marcantonio
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 4.271

9.  Predisposing factors for delirium in the surgical intensive care unit.

Authors:  M Aldemir; S Ozen; I H Kara; A Sir; B Baç
Journal:  Crit Care       Date:  2001-09-06       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.